U.S. Markets close in 2 hrs 11 mins

The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron

Zacks Equity Research

For Immediate Release

Chicago, IL –September 23, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Target TGT, Illumina ILMN, T-Mobile US TMUS, Xcel Energy XEL and Regeneron Pharmaceuticals REGN.

Here are highlights from Friday’s Analyst Blog:

Top Research Reports for Target, Illumina and T-Mobile US

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Target, Illumina and T-Mobile US. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Target’s shares have outperformed the Zacks Retail- Discount & Variety industry in the year-to-date period (63.2% vs. 39.5%). The Zacks analyst thinks that the company is fast acclimatizing with the changing retail ecosystem and deploying resources to enhance omni-channel capacities, come up with new brands, remodel stores and expand same-day delivery options.

These bode well for the company that posted better-than-expected second-quarter fiscal 2019 results, wherein both the top and the bottom lines grew year over year. The company witnessed healthy traffic and impressive comparable digital channel sales. Sturdy performance prompted management to lift fiscal 2019 earnings view.

Management now envisions comparable sales to increase about 3.4% both in the third quarter and in the second half. However, we believe that incremental investments, higher wages and rise in costs due to new fulfillment options may squeeze margins.

(You can read the full research report on Target here >>>)

Shares of Illumina have lost 4.4% in the past six months, outperforming the Zacks Medical - Biomedical and Genetics industry’s fall of 12.2%. The Zacks analyst believes llumina continues to put up a robust performance across a broad range of sequencing applications.

The launch of Veriseq NIPT v2 and the company’s partnership with AnchorDx in the second quarter also drive optimism. Over the past year, Illumina’s shares have been outperforming the industry it belongs to. With respect to quarterly results, Illumina exited the second quarter of 2019 on a solid note, with earnings and revenues beating the Zacks Consensus Estimate.

It is encouraging to note that revenues grew across the company’s high and low throughput categories. On the flip side, contraction in both margins and a year-over-year decline in Service and Other Revenues are concerns.

(You can read the full research report on Illumina here >>>).

T-Mobile US’ shares have gained 7% in the past three months, underperforming the Zacks National Wireless industry’s rise of 7.9% over the same period. The Zacks analyst believes that the New T-Mobile will have about 127 million customers and a strong closing balance sheet, and is expected to heighten competition in the 5G space.

T-Mobile has cleared most of the regulatory and shareholder approvals for its game-changing merger with Sprint. T-Mobile continues to invest in its network and prepare for nationwide 5G with the aggressive rollout of its 600 MHz spectrum. The wireless carrier has introduced 5G millimeter wave network in six cities including New York and Los Angeles.

However, a highly competitive and saturated U.S. wireless market remains a major headwind. Intensifying competition is likely to limit its ability to attract and retain customers and may affect operating results. The company launched several low-priced service plans which have enhanced its revenues, but not significantly improved the bottom line.

 (You can read the full research report on T-Mobile US here >>>).

Other noteworthy reports we are featuring today include Xcel Energy and Regeneron Pharmaceuticals.

Just Released: Zacks’ 7 Best Stocks for Today

Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.6% per year.

These 7 were selected because of their superior potential for immediate breakout.

See these time-sensitive tickers now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339



Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Xcel Energy Inc. (XEL) : Free Stock Analysis Report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
Target Corporation (TGT) : Free Stock Analysis Report
T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research